United Kingdom Parliament
Publications & records
Advanced search
 HansardArchivesResearchHOC PublicationsHOL PublicationsCommittees
Select Committee on Health Minutes of Evidence


Memorandum by British American Tobacco

THE TOBACCO INDUSTRY AND THE HEALTH RISKS OF SMOKING (TB 28)

ROTHMANS' OWN RESEARCH

  127.  For more than 40 years Rothmans companies in the UK have contributed to research on questions relating to causation and the mechanisms of diseases which have been associated with smoking and the part that smoking might play in the development of these diseases in smokers. It has done this through its contribution to industry research (which is detailed at paragraphs 63 to 84 above) and the funding of independent research. It has also conducted its own research into the development of products which might be regarded as "safer", including research in response to the recommendations of the ISCSH.

  128.  Because of the important role Rothmans has played in carrying out or funding industry research, its own in-house research cannot be seen in its proper context without an appreciation of the industry research that was being carried out at any particular time. This is especially so since Rothmans' companies have been principal members of the relevant tobacco industry association since its inception in 1956 and, as such, they have played a full part in determining and contributing to the industry's research efforts since that time.

  129.  For the purpose of this memorandum, it is only possible to give a brief summary of the research conducted by Rothmans in response to concerns about smoking and health. For ease of understanding, the research is summarised on a decade by decade basis.

1950s

  130.  In the 1950s Rothmans' research was carried out at its laboratories in the London area. The research focused on:

    —  developing a research strategy to analyse the chemical constituents of smoke (this included discussions with the Home Office, with regard to proposals for tests involving newts to assess the biological activity of smoke fractions) which would be used as a guide to the biological efficiency of filters;

    —  developing new analytical and physical testing methods, including routine methods with regard to nitrogen compounds and polyphenols; and

    —  conducting fundamental research into tobacco resins.

  131.  Rothmans also ensured that its scientists monitored closely the contemporaneous scientific literature and analysed what Rothmans could do in response to the same, through industry research and/or as an individual company.

1960s

  132.  Following the publication of the 1962 Royal College of Physicians' Report, Rothmans established a new scientific research division at Basildon. The first research director to be appointed at Basildon was a Dr AJ Lindsey who, in his previous academic post, had been one of the first scientists to identify traces of the carcinogen benzo(a)pyrene in cigarette smoke. Examples of the research conducted at Basildon are set out below.

  133.  Smoke chemistry research: Rothmans' research focused on the chemical composition of smoke, seeking to identify the chemical constituents which might contribute to disease in smokers and then to reduce or eliminate such constituents from smoke.

  134.  Biological tests: Rothmans' policy on product modification at this time involved the use of bioassay models as a guide towards achieving changes in the product. The object was to find techniques for reducing biological activity. Whilst bioassay is a sound procedure, and one which was followed by Rothmans alongside the scientific community for many years, it has its limitations. The principal difficulties lie in the failure of attempts, both within and outside the industry, to develop bioassay models in which exposure to cigarette smoke, or tar, results in changes which correlate with the development of any of the diseases which epidemiology has associated with smoking in humans. Further, research into the biological mechanisms of disease has failed, thus far, to demonstrate coherent biological mechanisms to explain the connection between smoking and disease in humans. In consequence, at best, only bioassay methods of uncertain relevance to human disease were available and, therefore, the interpretation of results in terms of product modification was difficult.

  135.  Whilst Rothmans acknowledged that contemporary bioassay models were the best available means at this time and continued (in line with other companies and the scientific community generally) to use these methods, it also researched and developed new means (within the broad scope of bioassay) of testing the biological activity of smoke. These new means included: rat trachea tests; alveolar macrophage toxicity tests; inhibition of mitochondrial respiration tests and a variation of ciliastasis tests. These techniques were used in Rothmans' product development programme, including in later years the assessment of cigarettes containing substitute materials. Various papers were published by Rothmans in scientific journals concerning the methodology of these new techniques.

  136.  Tar reduction: As results from the mouse skin-painting experiments conducted by the TRC and others accumulated, Rothmans reached the conclusion that, as these experiments were not providing a clear indication of a simple and practical means to change the composition of tar, the best approach was to continue to reduce the quantity of tar delivered by cigarettes. This view was also reached by a number of independent scientists throughout the world (and was later to be confirmed in the 1972 Report of the Standing Scientific Liaison Committee on Smoking and Health).

  137.  Rothmans therefore focused its research efforts upon possible means of achieving further overall reductions in the tar yields of cigarettes. This included the development of different types of cigarette filters, including charcoal, paper and cellulose acetate filters. Research was also carried out in respect of the use of different blends of tobacco, crushed rolled stems, tobacco sheet, the use of expanded tobacco and various methodologies to improve filter efficiency (including filter ventilation and the use of porous cigarette papers). It was recognised, however, that such modifications, in order to be of any potential benefit, also had to be capable of manufacture and acceptable to the consumer.

1970s

  138.  To respond to consumer concerns, and to suggestions made by the ISCSH, Rothmans considered many possibilities for product modification during this period, including low tar/low nicotine cigarettes, low tar/normal nicotine cigarettes, low nicotine cigarettes and low "irritant" cigarettes.

  139.  Substitute materials; Rothmans, along with other UK companies, developed a substitute material for tobacco in line with the recommendations of the ISCSH. Initially Rothmans' research efforts concentrated on its own development of a substitute material named Astec (a calcium alginate-based product, which was derived from seaweed). This work eventually ceased, however, after an alternative substitute material Cytrel (which had already been developed by American Celanese, a US manufacturing company) became available to Rothmans.

  140.  In 1974, Rothmans entered into a joint venture with Gallaher to undertake a wide-ranging programme of toxicological and biological tests into Cytrel. These tests were carried out in accordance with the 1975 Independent Scientific Committee Guidelines on Testing of Substitutes, which were issued to assist the tobacco companies in the conduct of their research and in making submissions to the Committee for approval of the use of substitute materials in cigarettes. This programme involved smoke chemistry tests, chronic, sub-acute and acute inhalation tests in animals, reproductive studies and long and short term clinical trials. Rothmans engaged a panel of external expert scientists to advise on the design and execution of this testing programme. Results of the testing programme were published in the scientific literature.

  141.  This development work required both a significant financial investment and the services of a number of contract laboratories and also occupied a substantial amount of the time of many of Rothmans' scientists for several years.

  142.  In early 1977, the ISCSH approved the use of Cytrel in cigarettes and, in July 1977, Rothmans launched onto the UK market its Cytrel brand, Peer. At the same time, a further eleven substitute brands (containing Cytrel or another substitute material known as NSM (new Smoking Material)) were launched by other companies.

  143.  After an initially promising start, sales of the brands containing tobacco substitutes were low (totalling 2 per cent of market share) and most were soon withdrawn. This may be attributable in part to the fact that, coinciding with the launch, the Health Education Council ran a negative publicity campaign whose effect was to discourage smokers from using the new brands and also the fact that, contrary to previous consumer expectations, cigarettes containing substitutes were no cheaper than conventional cigarettes (the same level of duty was levied on substitutes as on conventional cigarettes).

  144.  Despite its failings (in terms of commercial viability), Rothmans' Peer remained on sale until 1984 and was the last of the twelve brands containing substitute materials to be withdrawn from the market.

1980s

  145.  During this period, in response to scientific and regulatory developments, and the voluntary agreements reached between the Government and the tobacco companies to reduce tar yields and to work with the ISCSH (which recommend further research into smoke chemistry and the benefits of reduced tar, nicotine and carbon monoxide yields), Rothmans' research concentrated on increasing the acceptability of lower yielding products. This work included:

    —  exploring the relative acceptability of different techniques for reducing cigarette yields. This involved establishing methods for comparing the acceptability of different product modifications and setting up a series of consumer panels to provide guidance on the sensory properties of developmental cigarettes;

    —  (following a recommendation by the ISCSH) developing a cigarette in which nicotine was reduced to a lesser extent than the reduction in level of tar (ie a low tar to nicotine ratio cigarette). These cigarettes were marketed under the brand of Rothmans Special in the early to mid 1980s;

    —  developing new methods of cigarette construction to maximise the flavour of low yielding products and also developing flavours (containing minute quantities of approved additives);

    —  carrying out fundamental studies into how the flavour characteristics of cigarettes are perceived by smokers (in order to provide models for the design of new, lower yielding cigarettes); and

    —  assessing new bioassay tests developed by the scientific community and using these and other established tests to monitor the biological activity of experimental and commercial cigarettes.

  146.  During this period, Rothmans retained and expanded the panel of expert scientists, initially recruited to advise on testing Cytrel, to provide guidance on the content and execution of its continuing research programme. Rothmans' also provided support to a number of independent institutions to provide information directly relevant to its research programme and to allow these institutions to further their own programmes. The scientists involved were encouraged to publish their results in the scientific literature.

1990s

  147.  As the progression to lower tar yields continued, Rothmans maintained its efforts to improve the acceptability of products with lower tar yields. Examples of relevant research include:

    —  exploring the relative acceptability of different techniques for reducing cigarette yields. This involved establishing methods for comparing the acceptability of different product modifications and setting up a series of consumer panels to provide guidance on the sensory properties of developmental cigarettes;

    —  continuing research into acceptable low tar and ultra-low tar cigarettes including investigating concepts such as tobacco rods where the blend is varied in composition along the length so that there are high flavour and high nicotine tobaccos in the portion smoked first and lower yielding tobaccos in the later portion;

    —  conducting research into filters, including examining the possibilities of increasing filter efficiency by making use of the change in retention efficiency brought about by the deposition of tar onto the filter fibres for different designs. In addition, filter development work was undertaken with the aim of increasing retention efficiency puff by puff in order to permit the optimisation of tar yield profiles for cigarettes; and

    —  conducting further studies into how the flavour characteristics of cigarettes are perceived by smokers (in order to provide models for the design of new, lower yielding cigarettes).


 
previous page contents next page

House of Commons home page Parliament home page House of Lords home page search page enquiries

© Parliamentary copyright 2000
Prepared 28 February 2000